Document is current
Any future updates will be listed below
-
Authors
Massy, Ziad A. https://orcid.org/0000-0001-5771-5996
Kolla, Epiphane
Ferrières, Jean
Bruckert, Eric
Lambert, Oriane
Mansencal, Nicolas
Laville, Maurice
Frimat, Luc
Fouque, Denis
Combe, Christian
Pecoits-Filho, Roberto
Stengel, Bénédicte
Liabeuf, Sophie
,
-
Funding
Funding for this research was provided by:
Amgen Nederland
Else Kröner-Fresenius-Stiftung
GlaxoSmithKline
Lilly Deutschland
Otsuka America Pharmaceutical
Baxter Nederland
Merck Sharp and Dohme
Sanofi
- License Information
-
More Information
Article History
Received: 10 April 2021
Accepted: 27 May 2021
First Online: 11 June 2021
Declarations
:
: CKD-REIN is supported by a public–private partnership with seven academics and support from nine pharmaceutical companies (Merck Sharp & Dohme-Chibret [MSD France], Amgen, Fresenius Medical Care, GlaxoSmithKline [GSK], Baxter, Lilly France, Otsuka Pharmaceutical, Vifor Fresenius, and Sanofi-Genzyme). Dr. Massy reports public funding, grants to charities, travel and accommodation support from Amgen; public funding, travel and accommodation support from Sanofi-Genzyme; and grants from the French Government, MSD, GSK, Lilly, FMC, Baxter, Outsuka, and AstraZeneca. Dr. Ferrieres reports personal fees from Amgen, Sanofi, Merck, and Servier. Dr. Bruckert reports personal fees from MSD, Akcea, Servier, Sanofi Aventis, Amgen, Genfit, Regeneron, Mylan, Danone, and Silence Therapeutics; and grants and personal fees from Aegerion Amryt. Dr. Fouque reports personal fees from Sanofi, Vifor, Fresenius, Lilly; grants and personal fees from kabi; and personal fees and non-financial support from AstraZeneca. Dr. Pecoits-Filho reports grants from Fresenius Medical Care; non-financial support from AstraZeneca, Akebia, Novo Nordisk, and Boehringer-Lilly. Dr. Stengel reports grants from Amgen, AstraZeneca, Fresenius medical care, Otsuka, Vifor Fresenius, and GSK. Drs. Kolla, Lambert, Mansencal, Laville, Frimat, Combe, and Liabeuf have nothing to disclose.
: The study protocol was approved by the French National Institute of Health and Medical Research (Inserm) institutional review board (IRB00003888).
: Patients provided informed consent to participate.
: This work has not been published previously and is not under consideration for publication elsewhere. The manuscript has been approved by all authors and by the responsible authorities where the work was carried out. If the article is accepted, it will not be published elsewhere by the authors, including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.
